Stockscreener 앱 받기
30.04
0.00%
0.00
시간 외 거래:
30.09
0.05
+0.17%
전일 마감가:
$30.04
열려 있는:
$30.04
하루 거래량:
258.87K
Relative Volume:
0.65
시가총액:
$1.52B
수익:
$400.79M
순이익/손실:
$-35.58M
주가수익비율:
-42.40
EPS:
-0.7085
순현금흐름:
$-15.09M
1주 성능:
-3.22%
1개월 성능:
-9.42%
6개월 성능:
-7.85%
1년 성능:
+4.63%
1일 변동 폭
$29.73
$30.77
1주일 범위
$29.73
$31.38
52주 변동 폭
$23.15
$40.71
이뮤노코어 홀딩스 Stock (IMCR) Company Profile
명칭
Immunocore Holdings Plc Adr
전화
01235 5430281
주소
90 PARK DRIVE, OXFORDSHIRE
Compare IMCR vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMCR
Immunocore Holdings Plc Adr
|
30.04 | 1.52B | 400.79M | -35.58M | -15.09M | -0.7085 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
이뮤노코어 홀딩스 Stock (IMCR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-16 | 다운그레이드 | Jefferies | Buy → Hold |
| 2026-01-07 | 업그레이드 | UBS | Sell → Buy |
| 2025-10-31 | 개시 | Wells Fargo | Overweight |
| 2025-09-18 | 재개 | Guggenheim | Neutral |
| 2025-08-25 | 재개 | Jefferies | Buy |
| 2025-05-27 | 개시 | Deutsche Bank | Buy |
| 2024-12-13 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-11-11 | 다운그레이드 | Mizuho | Outperform → Neutral |
| 2024-10-24 | 개시 | UBS | Sell |
| 2024-10-07 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-04-29 | 개시 | Leerink Partners | Outperform |
| 2023-11-20 | 재개 | JP Morgan | Overweight |
| 2023-11-02 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-10-31 | 개시 | Robert W. Baird | Outperform |
| 2023-09-13 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-09-13 | 개시 | Needham | Buy |
| 2023-08-16 | 개시 | CapitalOne | Overweight |
| 2023-07-17 | 개시 | Canaccord Genuity | Hold |
| 2023-03-31 | 개시 | Mizuho | Buy |
| 2023-03-30 | 개시 | Guggenheim | Buy |
| 2023-03-24 | 개시 | Bryan Garnier | Buy |
| 2022-12-16 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-11-30 | 개시 | Barclays | Overweight |
| 2022-09-09 | 개시 | Morgan Stanley | Overweight |
| 2022-09-08 | 개시 | Ladenburg Thalmann | Buy |
| 2022-08-08 | 개시 | Cowen | Outperform |
| 2022-08-02 | 개시 | BTIG Research | Buy |
| 2022-02-08 | 개시 | H.C. Wainwright | Buy |
| 2021-10-20 | 개시 | Oppenheimer | Outperform |
| 2021-03-02 | 개시 | Goldman | Neutral |
| 2021-03-02 | 개시 | JP Morgan | Overweight |
| 2021-03-02 | 개시 | Jefferies | Buy |
모두보기
이뮤노코어 홀딩스 주식(IMCR)의 최신 뉴스
Immunocore (IMCR) upgraded to strong buy: Here's what you should know - MSN
Jefferies downgrades Immunocore stock rating on revenue concerns - Investing.com South Africa
Immunocore at Leerink Conference: Strategic Growth and Innovation - Investing.com
Q1 Earnings Forecast for Immunocore Issued By HC Wainwright - Defense World
What is HC Wainwright's Estimate for Immunocore Q1 Earnings? - MarketBeat
Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
FY2027 EPS Estimates for Immunocore Cut by HC Wainwright - MarketBeat
Immunocore to present at upcoming investor conferences - GlobeNewswire Inc.
Immunocore (NASDAQ:IMCR) Price Target Raised to $75.00 at Needham & Company LLC - Defense World
Immunocore Q4 Earnings Call Highlights - Yahoo Finance
Immunocore Holdings earnings missed by $0.40, revenue fell short of estimates - Investing.com South Africa
RXRX Q4 Loss Narrower Than Expected, Revenues Increase Y/Y, Stock Up - Finviz
JAZZ Stock Rises as Q4 Earnings & Sales Top Expectations - Finviz
Repligen's Q4 Earnings Beat Estimates, Revenues Surge Y/Y - Finviz
Apellis Q4 Loss Wider Than Expected, Revenues Decline Y/Y - Finviz
Earnings call transcript: Immunocore Holdings Q4 2025 reveals strong growth, stock dips By Investing.com - Investing.com South Africa
Earnings call transcript: Immunocore Holdings Q4 2025 reveals strong growth, stock dips - Investing.com India
Immunocore earnings ahead as melanoma pipeline advances By Investing.com - Investing.com India
Immunocore earnings ahead as melanoma pipeline advances - Investing.com
Madrigal Q4 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Down - Finviz
Immunocore (NASDAQ:IMCR) CAO John Goll Sells 698 Shares - MarketBeat
Leger Tina Amber St Sells 1,000 Shares of Immunocore (NASDAQ:IMCR) Stock - MarketBeat
Immunocore (NASDAQ:IMCR) CEO Bahija Jallal Sells 11,474 Shares - MarketBeat
David Berman Sells 5,965 Shares of Immunocore (NASDAQ:IMCR) Stock - MarketBeat
[144] Immunocore Holdings plc SEC Filing - Stock Titan
Immunocore (IMCR) upgraded to strong buy: Here's why - MSN
Immunocore (IMCR) Upgraded to Strong Buy: Here's Why - Yahoo Finance
SNY Stock Falls After Board Suddenly Makes Leadership Change - Finviz
Immunocore Holdings PLC Sponsored ADR $IMCR Stock Holdings Lifted by Candriam S.C.A. - MarketBeat
Immunocore Holdings PLC Sponsored ADR $IMCR Shares Sold by Principal Financial Group Inc. - MarketBeat
Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
GSK Gets EU Approval for Expanded Use of Nucala in COPD - Finviz
HC Wainwright Weighs in on Immunocore FY2030 Earnings - Defense World
Bristol-Myers Stock Up as Q4 Earnings and Revenues Beat Estimates - Finviz
HC Wainwright Predicts Immunocore FY2030 Earnings - MarketBeat
NVO Q4 Earnings & Sales Beat Estimates, Stock Down on Poor 2026 View - Finviz
Acadia Expects Negative CHMP Opinion for Rett Syndrome Drug in EU - The Globe and Mail
NVO's CagriSema Outshines Semaglutide in Phase III Diabetes Study - Finviz
Immunocore Holdings (IMCR) is One of the Best Small Cap Stocks Ready to Explode in 2026 - Finviz
Immunocore announces resignation of head of research and development By Investing.com - Investing.com South Africa
Immunocore announces resignation of head of research and development - Investing.com
Immunocore announces executive leadership changes in R&D - Investing.com
TEVA's Q4 Earnings Beat, Branded Drugs Drive Revenue Growth - Finviz
Immunocore Holdings plc Share Price ADS Each Rep 1 Ord Share SPON - Hargreaves Lansdown
BHC's Late-Stage Liver Cirrhosis Studies Fail, Stock Down - The Globe and Mail
이뮤노코어 홀딩스 (IMCR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):